Related Experiment Video
Updated: May 5, 2026

Modeling Ascending Vaginal Infection, Preterm Birth, and Neonatal Morbidity in Mice
Published on: October 10, 2025
Antibiotics for preterm rupture of membranes
Sara Kenyon1, Michel Boulvain, James P Neilson
1School of Health and Population Sciences, University of Birmingham, Public Health Building, Edgbaston, UK, B15 2TT.
Insights
Antibiotics for preterm rupture of membranes (PROM) reduce short-term neonatal infections and delay birth, but do not lower perinatal mortality. Co-amoxiclav is linked to increased necrotising enterocolitis risk in newborns.
Area of Science:
- Obstetrics and Gynecology
- Neonatal Medicine
- Pharmacology
Background:
- Premature birth is a leading cause of neonatal morbidity and mortality.
- Subclinical infection is a known complication of preterm rupture of membranes (PROM).
- Maternal antibiotic therapy for PROM may reduce infectious complications and delay labor but carries risks.
Purpose of the Study:
- To assess the immediate and long-term impacts of antibiotic administration in women with PROM before 37 weeks gestation.
- To evaluate effects on maternal infectious morbidity, neonatal outcomes (morbidity and mortality), and long-term childhood development.
Main Methods:
- Systematic review and meta-analysis of 22 randomized controlled trials (RCTs) involving 6872 women and neonates.
- Searched the Cochrane Pregnancy and Childbirth Group's Trials Register.
- Included RCTs comparing antibiotics with placebo, and trials of different antibiotics; some trials without placebo were included for perinatal death outcomes.
Main Results:
- Antibiotic use significantly reduced chorioamnionitis and the incidence of birth within 48 hours and seven days of randomization.
- Neonatal morbidity markers, including infection, surfactant use, oxygen therapy, and abnormal cerebral ultrasound, were significantly reduced.
- Co-amoxiclav was associated with a higher risk of neonatal necrotising enterocolitis; long-term childhood health showed minimal impact from antibiotics.
Conclusions:
- Routine antibiotic prescription for PROM prolongs pregnancy and improves short-term neonatal outcomes, despite no reduction in perinatal mortality.
- Long-term childhood benefits are not evident, but short-term gains support routine antibiotic use.
- Co-amoxiclav should be avoided due to increased risk of neonatal necrotising enterocolitis; the optimal antibiotic choice remains unclear.
Background:
Premature birth carries substantial neonatal morbidity and mortality. Subclinical infection is associated with preterm rupture of membranes (PROM). Prophylactic maternal antibiotic therapy might lessen infectious morbidity and delay labour, but could suppress labour without treating underlying infection.
Objectives:
To evaluate the immediate and long-term effects of administering antibiotics to women with PROM before 37 weeks, on maternal infectious morbidity, neonatal morbidity and mortality, and longer-term childhood development.
Search Methods:
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 September 2013).
Selection Criteria:
Randomised controlled trials comparing antibiotic administration with placebo that reported clinically relevant outcomes were included as were trials of different antibiotics. Trials in which no placebo was used were included for the outcome of perinatal death alone.
Data Collection And Analysis:
We extracted data from each report without blinding of either the results or the treatments that women received. We sought unpublished data from a number of authors.
Main Results:
We included 22 trials, involving 6872 women and babies.The use of antibiotics following PROM is associated with statistically significant reductions in chorioamnionitis (average risk ratio (RR) 0.66, 95% confidence interval (CI) 0.46 to 0.96, and a reduction in the numbers of babies born within 48 hours (average RR 0.71, 95% CI 0.58 to 0.87) and seven days of randomisation (average RR 0.79, 95% CI 0.71 to 0.89). The following markers of neonatal morbidity were reduced: neonatal infection (RR 0.67, 95% CI 0.52 to 0.85), use of surfactant (RR 0.83, 95% CI 0.72 to 0.96), oxygen therapy (RR 0.88, 95% CI 0.81 to 0.96), and abnormal cerebral ultrasound scan prior to discharge from hospital (RR 0.81, 95% CI 0.68 to 0.98). Co-amoxiclav was associated with an increased risk of neonatal necrotising enterocolitis (RR 4.72, 95% CI 1.57 to 14.23).One study evaluated the children's health at seven years of age (ORACLE Children Study) and found antibiotics seemed to have little effect on the health of children.
Authors' Conclusions:
Routine prescription of antibiotics for women with preterm rupture of the membranes is associated with prolongation of pregnancy and improvements in a number of short-term neonatal morbidities, but no significant reduction in perinatal mortality. Despite lack of evidence of longer-term benefit in childhood, the advantages on short-term morbidities are such that we would recommend antibiotics are routinely prescribed. The antibiotic of choice is not clear but co-amoxiclav should be avoided in women due to increased risk of neonatal necrotising enterocolitis.
Related Concept Videos
Development of the Oral Microbiota
Acute Pyelonephritis II: Diagnostic Studies and Management
Mechanism of Antibiotic Resistance in MRSA
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Inhibitors of Gram-positive Cell Wall Synthesis

